FindTrial
Sign In

The control group received placebo (distilled water

3 trials

Sponsors

Health Ministry Drug and Pharmacy General Management, NOBEL Pharmacy

Conditions

Condition 1: Necrotizing enterocolitis. Condition 2: Sepsis. Condition 3: Hyperbilirubinemia. Necrotizing enterocolitis of fetus and newborn Bacterial sepsis of newborn Neonatal jaundice from breast milk inhibitorNecrotizing eneterocolitis, neonatal sepsis. Necrotizing enterocolitis of fetus and newborn, bacterial sepsis of newbornNeonatal hyperbilirubinemia. Neonatal jaundice from breast milk inhibitor

Phase 3

Outcome of Saccharomyces boulardii prophlaxis on necrotizing enterocolitis
Active, not recruitingIRCT2012071410279N1
Health Ministry Drug and Pharmacy General ManagementNecrotizing eneterocolitis, neonatal sepsis. Necrotizing enterocolitis of fetus and newborn, bacterial sepsis of newborn
Start: 2010-10-01Target: 208Updated: 2018-02-22
Saccharomyces boulardii's efficiency on hyperbilirubinemia
Active, not recruitingIRCT2012123010279N2
Health Ministry Drug and Pharmacy General ManagementNeonatal hyperbilirubinemia. Neonatal jaundice from breast milk inhibitor
Start: 2012-07-20Target: 150Updated: 2018-02-22
Outcome of synbiotics on necrotizing enterocolitis, sepsis
Active, not recruitingIRCT2013062710279N3
NOBEL PharmacyCondition 1: Necrotizing enterocolitis. Condition 2: Sepsis. Condition 3: Hyperbilirubinemia. Necrotizing enterocolitis of fetus and newborn Bacterial sepsis of newborn Neonatal jaundice from breast milk inhibitor
Start: 2012-10-01Target: 210Updated: 2018-02-22